DNAI3: A Potential Drug Target for Various Diseases (G126820)

Target Name: DNAI3

NCBI ID: G126820

DNAI3

DNAI3: A Potential Drug Target for Various Diseases

DNAI3 (DIC3), a protein that belongs to the immune response gene family, has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

The DNAI3 gene is located on the X chromosome and has been shown to play a role in the immune response and inflammation. Mutations in the DNAI3 gene have been linked to various autoimmune disorders, including systemic lupus erythematosus, a type of autoimmune disease that affects the skin, joints, and other organs.

In addition to its role in autoimmune disorders, DNAI3 has also been shown to contribute to cancer development and progression. For example, studies have shown that high levels of DNAI3 are associated with an increased risk of developing certain types of cancer, such as breast cancer and ovarian cancer.

Furthermore, DNAI3 has also been linked to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms, including cognitive impairment, mood disorders, and behavioral changes.

Given the potential links to autoimmune disorders, cancer, and neurodegenerative diseases, researchers are actively exploring the use of DNAI3 as a drug target or biomarker. One approach is to target DNAI3 directly with small molecules or antibodies to reduce inflammation and improve immune function. Another approach is to use DNAI3 as a diagnostic biomarker to identify early signs of disease and monitor the effectiveness of treatments.

In addition to its potential therapeutic applications, DNAI3 also has significant potential as a biomarker for various diseases. Its level has been shown to be elevated in the blood and urine of individuals with cancer, making it a promising indicator of disease progression. Furthermore, DNAI3 has been shown to be downregulated in the blood of individuals with autoimmune disorders, making it a potential indicator of disease activity.

Overall, DNAI3 is a promising drug target or biomarker for the treatment of various diseases. Further research is needed to fully understand its role in the immune response and inflammation and to develop safe and effective treatments.

Protein Name: Dynein Axonemal Intermediate Chain 3

Functions: Acts as a negative regulator of cell migration, invasion, and metastasis downstream of p53/TP53, through inhibition of Arp2/3 complex-mediated actin polymerization (PubMed:32128961). Via its association with the multisubunit axonemal dynein complex, is potentially involved in the regulation of cilia function (By similarity). May play a role in osteogenesis of dental tissue-derived mesenchymal stem cells (By similarity)

The "DNAI3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAI3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets